BioWorld MedTech

Nov. 20, 2015

SCS Teeming with Competition: St. Jude earns FDA nod for Proclaim, looks to gain ground within SCS market

With an FDA approval of its Proclaim elite spinal cord stimulation (SCS) system in hand, St. Jude Medical Inc. (St. Paul, Minn.) could find itself poised to take a greater share of the SCS market. Read More

Inside the Beltway: Support for LDT discussion draft broad, but FDA wary of deadlines

Targeting the microbiome: Nutritional value of food depends critically on the gut of the eater

Domestic Products have edge: Chinese firms encouraged to pursue international investment opportunities

Old drug performing new tricks: Genentech explores new delivery for longstanding wet AMD drug

IPO floodgates open: Success of JOBS Act leading to higher IPO costs for biotechs

Agreements/contracts: AdvaMed signs strategic cooperation accord with China

Financings: Fractyl extends series C, for round total of $57M

Product briefs

Briefly Noted

MDD's Diagnostics Extra

Today's news in brief

BioWorld

BioWorld briefs for May 21, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...